LGT Financial Advisors’s AbbVie ABBV Stock Holding History

LGT Financial Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-500	Closed	-$67.4K	–	929
2023 Q2	$67.4K	Buy	+500	New	+$73.3K	0.07%	154

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

LGT Financial Advisors's ABBV Position: Q2 2026 in Review

LGT Financial Advisors increased its AbbVie (ABBV) stake by 34% in Q2 2026, buying an estimated $109K and bringing the position to 2,022 shares worth $509K. The position accounts for 2.69% of the portfolio, ranked #6.

LGT Financial Advisors first reported a position in ABBV in Q4 2022 and has held it in 15 quarters since. 4,215 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

LGT Financial Advisors held 2,022 shares of AbbVie worth $509K as of Q2 2026.
LGT Financial Advisors bought 508 AbbVie shares in Q2 2026, an estimated $109K.
AbbVie made up 2.69% of LGT Financial Advisors's portfolio in Q2 2026, its #6 holding.
LGT Financial Advisors first reported a position in AbbVie in Q4 2022 and has held it in 15 quarters since.
4,215 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on LGT Financial Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.